Перспективы применения ивабрадина в лечении больных с острым инфарктом миокарда

1. Оганов Р.Г. Профилактика сердечно-сосудистых заболеваний: возможности практического здравоохранения. Кардиоваскул. терапия и профилактика. 2002; 1: 5–9.
2. D’Agostino RB, Grundy S, Sullivan LM et al. CDH Risk Prediction Group. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001; 286: 180–7.
3. Higgins M. Patients, families and populations at high risk for coronary heart disease. Eur Heart J 2001; 22: 1682–90.
4. Шальнова С.А., Деев А.Д., Оганов Р.Г. и др. Частота пульса и смертность от сердечно-сосудистых заболеваний у российских мужчин и женщин. Результаты эпидемиологического исследования. Кардиология. 2005; 10: 45–50.
5. Kannel W, Kannel C, Paffenbarger R et al. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J 1987; 113: 1489–94.
6. Seccareccia F, Pannozzo F, Dima F et al. Heart rate as a predictor of mortality: the MATISS Project. Am J Public Health 2001; 91: 1258–63.
7. Singh BN. Morbidity and Mortality in Cardiovascular Disorders: Impact of Reduced Heart Rate. J Сardiovasc Pharmacol Therapeut 2001; 6 (4): 313–31.
8. Wilhelmsen L, Berglund G, Elmfeldt D et al. The multifactor primary prevention trial in Goteborg, Sweden. Eur heart J 1986; 7: 279–88.
9. Лилли Л. Патофизиология заболеваний сердечно-сосудистой системы. Пер. с англ. М.: БИНОМ, 2003; с. 582.
10. Disegni E, Goldbourt U, Reicher-Reiss H et al. The predictive value of admission heart rate on mortality in patients with acute myocardial infarction. SPRINT Study Group (Secondary Prevention Reinfarction Israeli Nifedipine Trial). J Clin Epidemiol 1995; 48: 1197–205.
11. Hjalmarson A, Gilpin EA, Kjekshus J et al. Influence of heart rate on mortality after acute myocardial infarction. Am J Cardiol 1990; 65: 547–53.
12. Lee KL, Woodlief LH, Topol EJ et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction: results from an international trail of 41,021 patients. GUSTO-I Investigators. Circulation 1995; 91: 1659–68.
13. Marchioli R, Avanzini F, Barzi F et al. Assessment of absolute risk of death after myocardial infarction by use of multiplerisk-factor assessment equations: GISSI-Prevenzione mortality risk chart. Eur Heart J 2001; 22: 2085–103.
14. Saraiva F, Antonio N, Lourenço C et al. Heart rate and prognosis in acute coronary syndromes. Rev Port Cardiol 2010; 29 (7–8): 1101–19.
15. Ерофеева С.Б., Манешина О.А., Белоусов Ю.Б. Место ивабрадина – первого If-ингибитора избирательного и специфического действия, в лечении сердечно-сосудистых заболеваний. Качественная клиническая практика. 2006; 1: 10–22.
16. Лопатин Ю.М. Изменятся ли наши взгляды на контроль частоты сердечных сокращений у больных стабильной стенокардией после исследования BEAUTIFUL. Кардиоваскул. терапия и профилактика. 2008; 8: 70–4.
17. Graham I, Atar D, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2007; 28: 2375–414.
18. Brown HF, Di Francesco D, Noble SJ. How does adrenaline accelerate the heart? Nature 1979; 280: 235–6.
19. Mulder P, Barbier S, Chagraoui A et al. Long-term heart rate reduction induced by the selective If current inhibitor ivabradine improves left ventricular dysfunction and intrinsic myocardial structure in congestive heart failure. Circulation 2004; 109: 1674–9.
20. Borer JD, Fox K, Jailon P et al. Antianginal and antiischemic effects of ivabradin, an If inhibitor in stable angina. Circulation 2003; 107: 817–23.
21. Fox K, Ford I, Steg PG et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 807–16.
22. Lopez-Bescos L. Long-term safety and antianginal efficacy of the If current inhibitor ivabradine in patients with chronic stable angina. Eur Heart J 2004; 25: 876.
23. Ruzyllo W, Ford I, Tendera M et al. Antianginal and antiischemic effects of the If current inhibitor ivabradine compared to amlodipine as monotherapy in patients with chronic stable angina: A 3-month randomised, controlled, double-blind, multicenter trial. Eur Heart J 2004; 25: 878.
24. Tardif JC, Ford I, Tendera M et al. On behalf of INTIATIVE study investigators group. Antianginal and anti-ischemic effects of the If current inhibitor ivabradine compared to atenolol as monotherapies in patients with chronic stable angina. Eur Heart J 2003; 24: 186.
25. Tardif JC, Ponikowski P, Kahan T et al. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J 2009; 30 (5): 540–8.
26. Fox K, Ford I, Steg PG et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 2008; 372: 817–21.
27. Swedberg K, Komajda M, Bohm M et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376 (9744): 875–85.
28. Christensen LP, Zhang RL, Zheng W et al. Postmyocardial infarction remodeling and coronary reserve: effects of ivabradine and beta blockade therapy. Am J Physiol Heart Circ Physiol 2009; 297 (1): 322–30.
29. Dedkov EI, Zheng W, Christensen LP et al. Preservation of coronary reserve by ivabradine-induced reduction in heart rate in infarcted rats is associated with decrease in perivascular collagen. Am J Physiol Heart Circ Physiol 2007; 293 (1): 590–98.
30. Langenbach MR, Schmitz-Spanke S, Brockert M et al. Comparison of a beta-blocker and an If current inhibitor in rabbits with myocardial infarction. J Cardiovasc Surg (Torino) 2006; 47 (6): 719–25.
31. Zhang RL, Christensen LP, Tomanek RJ. Chronic heart rate reduction facilitates cardiomyocyte survival after myocardial infarction. Anat Rec (Hoboken) 2010; 293 (5): 839–48.
32. Heusch G, Skyschally A, Gres P et al. Improvement of regional myocardial blood flow and function and reduction of infarct size with ivabradine: protection beyond heart rate reduction. Eur Heart J 2008; 29 (18): 2265–75.
33. Терещенко С.Н., Косицына И.В., Голубев А.В. Возможность применения ивабрадина в комплексной терапии острого коронарного синдрома. Кардиология. 2008; 48 (7): 10–3.
34. Закирова А.Н., Карамова И.М., Николаева И.Е. и др. Эффективность и безопасность ивабрадина у пациентов с систолической дисфункцией левого желудочка, перенесших аортокоронарное шунтирование. Кардиоваскул. терапия и профилактика. 2009; 8: 125.
35. Fasullo S, Cannizzaro S, Maringhini G et al. Comparison of ivabradine versus metoprolol in early phases of reperfused anterior myocardial infarction with impaired left ventricular function: preliminary findings. J Card Fail 2009; 15 (10): 856–63.
36. Post F, Münzel T. Ivabradine – a new therapeutic option for cardiogenic shock? Herz 2009; 34 (3): 224–9.
37. Monnet X, Ghaleh B, Colin P et al. Effects of heart rate reduction with ivabradine on exercise-induced myocardial ischemia and stunning. J Pharmacol Exp Ther 2001; 299 (3): 1133–9.
38. Lucats L, Ghaleh B, Monnet X et al. Conversion of post-systolic wall thickening into ejectional thickening by selective heart rate reduction during myocardial stunning. Eur Heart J 2007; 28 (7): 872–9.
39. Iliuta L, Filipescu D, Moldovan H et al. Ivabradine versus betblockers in patients with conduction abnormalities or left ventricular dysfunction undergoing coronary artery bypass grafting. Eur Heart J 2009; 30: 916.
40. Сайганов С.А., Гришкин Ю.Н. Использование селективного ингибитора f-каналов ивабрадина для лечения синусовой тахикардии при острой сердечной недостаточности у больных ишемической болезнью сердца с нижним инфарктом миокарда. Кардиоваскулярная терапия и профилактика. 2010; 9 (3): 52–6.
41. Кондратьев А.И., Долгих В.Т., Стоцкий А.О. Эффективность ивабрадина в комплексном лечении осложненного острого коронарного синдрома на фоне сахарного диабета 2 типа. Тер. архив. 2010; 1: 27–31.
42. Dominguez-Rodriguez A, Fard SS, Abreu-Gonzalez P et al. Randomised, double-blind, placebo-controlled trial of ivabradine in patients with acute coronary syndrome: effects of the If current inhibitor ivabradine on reduction of inflammation markers in patients with acute coronary syndrome – RIVIERA trial study design and rationale. Cardiovasc Drugs Ther 2009; 23 (3): 243–7.

Е.Л.Школьник 

Московский государственный медико-стоматологический университет Минздравсоцразвития РФ